HC Wainwright Cuts CalciMedica (NASDAQ:CALC) Price Target to $16.00

CalciMedica (NASDAQ:CALC) had its price objective reduced by HC Wainwright from $20.00 to $16.00 in a report released on Monday morning, Benzinga reports. They currently have a buy rating on the stock.

Separately, Oppenheimer lifted their price target on shares of CalciMedica from $14.00 to $20.00 and gave the company an “outperform” rating in a report on Wednesday, July 10th.

CalciMedica Price Performance

CALC opened at $3.50 on Monday. CalciMedica has a 52-week low of $2.68 and a 52-week high of $8.38. The business’s fifty day moving average is $4.23 and its 200-day moving average is $4.63.

CalciMedica (NASDAQ:CALC) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.03. On average, research analysts expect that CalciMedica will post -2.21 earnings per share for the current year.

Insider Transactions at CalciMedica

In other CalciMedica news, major shareholder Sanderling Venture Partners Vi acquired 86,867 shares of the company’s stock in a transaction that occurred on Friday, November 1st. The stock was acquired at an average price of $3.75 per share, for a total transaction of $325,751.25. Following the acquisition, the insider now directly owns 814,300 shares in the company, valued at $3,053,625. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other CalciMedica news, major shareholder Sanderling Venture Partners Vi bought 86,867 shares of CalciMedica stock in a transaction on Friday, November 1st. The shares were purchased at an average cost of $3.75 per share, with a total value of $325,751.25. Following the acquisition, the insider now directly owns 814,300 shares of the company’s stock, valued at $3,053,625. The trade was a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO A. Rachel Leheny purchased 20,000 shares of the company’s stock in a transaction dated Friday, November 1st. The shares were acquired at an average cost of $3.75 per share, with a total value of $75,000.00. Following the purchase, the chief executive officer now directly owns 130,926 shares of the company’s stock, valued at approximately $490,972.50. The trade was a 0.00 % increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 312,944 shares of company stock worth $1,172,910. Insiders own 41.55% of the company’s stock.

Institutional Investors Weigh In On CalciMedica

An institutional investor recently raised its position in CalciMedica stock. Atria Investments Inc boosted its stake in CalciMedica, Inc. (NASDAQ:CALC) by 136.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 26,503 shares of the company’s stock after acquiring an additional 15,296 shares during the period. Atria Investments Inc owned 0.25% of CalciMedica worth $117,000 at the end of the most recent quarter.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.